MESOBLAST RECEIVES FDA CLEARANCE FOR PHASE 2 STEM CELL CLINICAL TRIAL

Source: Mesoblast Limited
Date: 18 December 2006

Summary:

Melbourne, Australia--Australia’s adult stem cell company, Mesoblast Limited (ASX:MSB), today announced that the United States Food and Drug Administration (US FDA) has cleared its Investigational New Drug Submission (IND) to commence a Phase 2 clinical trial for spinal fusion in the US.